2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
News|Articles|February 15, 2023
Takeda Completes $6 Billion Acquisition of Nimbus Therapeutics Subsidiary
Author(s)Pharmaceutical Technology Editors
Takeda’s acquisition of Nimbus Lakshmi will grant them rights to NDI-034858, an oral, selective allosteric TYK2 inhibitor being evaluated for the treatment of multiple autoimmune diseases.
Advertisement
Takeda and Nimbus Therapeutics, a clinical-stage pharmaceutical company, announced the completion of an acquisition agreement on Feb. 8, 2023. Announced in December 2022, the agreement includes Takeda’s acquisition of Nimbus Lakshmi, a wholly-owned subsidiary of Nimbus Therapeutics, and its tyrosine kinase 2 (TYK2) inhibitor TAK-279, formerly known as NDI-034858. Four billion dollars were paid upfront, with two additional billion-dollar payments to be made contingent on TAK-279 reaching net sales of $4 and $5 billion, respectively.
According to a company press release, TAK-279 is being evaluated for psoriasis as well as multiple other immune-mediated diseases. Takeda is expected to present Phase IIb data in the fourth quarter of the 2022 fiscal year, while a Phase III study in psoriasis is expected to begin sometime in 2023.
“With our plan to acquire announced in December [2022], we are excited to have promptly added TAK-279, a highly selective oral TYK2 inhibitor with truly transformative potential for patients in multiple diseases, to our late-stage pipeline,” said Ramona Sequeira, president, global portfolio division, Takeda, in the release. “This program closely aligns with our strategy and expertise in immune-mediated diseases, and we look forward to sharing more details of our development plans soon.”
Source:
Advertisement
Related to this article
Lilly is set to acquire Merida Biosciences for up to $2.875B, gaining a precision autoantibody-degrading platform led by phase 1 candidate MER511.
PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
Advertisement
Advertisement